Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for inborn disorder of purine or pyrimidine metabolism has been reported in the published literature.
No clinical trials have been registered for inborn disorder of purine or pyrimidine metabolism.
250 publications have been identified in PubMed for inborn disorder of purine or pyrimidine metabolism. Kisho has analyzed 166 by research type. Research spans Basic Science / Preclinical (72%), Gene Therapy / Novel Therapeutics (9%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 120 | 72% |
Data assembled from 3 of 12 sources · Last updated Sep 21, 2026, 2:35 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
New treatment approaches |
15 |
9% |
Clinical study results | 14 | 8% |
Research summaries | 9 | 5% |
Disease patterns and progression | 4 | 2% |
Testing and diagnosis research | 3 | 2% |
Patient case studies | 1 | 1% |
Kim MM (2026). [PMID: 41641807](https://pubmed.ncbi.nlm.nih.gov/41641807/). *J Feline Med Surg*. [Review / Meta-Analysis]
Wang Y (2026). [PMID: 40818322](https://pubmed.ncbi.nlm.nih.gov/40818322/). *Biomaterials*. [Basic Science / Preclinical]
Dubisova M (2026). [PMID: 41248423](https://pubmed.ncbi.nlm.nih.gov/41248423/). *Cancer research*. [Basic Science / Preclinical]
Bin Z (2026). [PMID: 41493014](https://pubmed.ncbi.nlm.nih.gov/41493014/). *Future medicinal chemistry*. [Basic Science / Preclinical]
Zhang K (2026). [PMID: 41330421](https://pubmed.ncbi.nlm.nih.gov/41330421/). *European heart journal*. [Clinical Trial Publication]
Stolte KN (2026). [PMID: 41517938](https://pubmed.ncbi.nlm.nih.gov/41517938/). *Clin Exp Dent Res*. [Basic Science / Preclinical]
Labroy M (2026). [PMID: 41506347](https://pubmed.ncbi.nlm.nih.gov/41506347/). *Mol Metab*. [Basic Science / Preclinical]
Ramesh V (2026). [PMID: 41444836](https://pubmed.ncbi.nlm.nih.gov/41444836/). *British journal of cancer*. [Epidemiology / Natural History]
Gan L (2026). [PMID: 41478201](https://pubmed.ncbi.nlm.nih.gov/41478201/). *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*. [Basic Science / Preclinical]
Zheng X (2026). [PMID: 41812427](https://pubmed.ncbi.nlm.nih.gov/41812427/). *Bioorg Chem*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning inborn disorder of purine or pyrimidine metabolism
Updated Aug 15, 2026
A new study explores the metabolic aspects of inborn errors of CoA biosynthesis, highlighting the common pathways that lead to divergent diseases. This research could inform future therapeutic strategies for these rare metabolic disorders.
A recent study emphasizes the importance of effective communication regarding treatment options for inborn errors of metabolism. This research highlights the need for improved dialogue between healthcare providers and patients to enhance understanding and decision-making.